Theravance Biopharma (TBPH) Misses Q4 EPS by 47c

Theravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($1.64), $0.47 worse than the analyst estimate of ($1.17). Revenue for the quarter came in at $4.5 million versus the consensus estimate of $4.84 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Securitize Corp (SECZ) PT Lowered to $10 at Benchmark as Stock Plummets Post Q2 Earnings
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c